An update on targeting Hippo-YAP signaling in liver cancer

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 3, 2012, Pages 243-247

  Liu, Angela M ^a   Xu, Zhi ^b   Luk, John M ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Roche RandD Center China Ltd   (China)

Author keywords

Hippo pathway; Liver cancer; Oncogene; YAP signaling

Indexed keywords

CELL PROTEIN; HIPPO YES ASSOCIATED PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INHIBITION; CELL MATURATION; CELL PROLIFERATION; HUMAN; LIVER CANCER; NONHUMAN; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84863298936     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.662958     Document Type: Review

References (23)

1. Liu AM, Xu MZ, Chen J, et al. Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets 2010;14:855-68
2. Benhamouche S, Curto M, Saotome I, et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 2010;24:1718-30
3. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50
4. Zhou D, Conrad C, Xia F, et al. Mst1 and Mst2 maintain hepatocytequiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009;16:425-38
5. Lu L, Li Y, Kim SM, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 2010;107:1437-42
6. Guo C, Tommasi S, Liu L, et al. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol 2007;17:700-5 (Pubitemid 46552245)
7. Lee KP, Lee JH, Kim TS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA 2010;107:8248-53
8. St John MA, Tao W, Fei X, et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999;21:182-6 (Pubitemid 29070363)
9. McPherson JP, Tamblyn L, Elia A, et al. Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. Embo J 2004;23:3677-88 (Pubitemid 39336289)
10. Cho WJ, Shin JM, Kim JS, et al. miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cel line through direct regulation of LATS2. Mol Cells 2009;28:521-7
11. Lee KH, Goan YG, Hsiao M, et al. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res 2009;315:2529-38
12. Zhao B, Li L, Tumaneng K, et al. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCFbeta-TRCP. Genes Dev 2010;24:72-85
13. Wang P, Bai Y, Song B, et al. PP1A-mediated dephosphorylation positively regulates YAP2 activity. PLoS One 2011;6:e24288
14. Mauviel A, Nallet-Staub F, Varelas X. Integrating developmental signals: a Hippo in the (path)way. Oncogene 2011;published online 29 August 2011; doi:10.1038/onc.2011.363
15. Tian W, Yu J, Tomchick DR, et al. Structural and functional analysis of the YAP-binding domain of human TEAD2. Proc Natl Acad Sci USA 2010;107:7293-8
16. Li Z, Zhao B, Wang P, et al. Structural insights into the YAP and. TEAD complex. Genes Dev 2010;24:235-40
17. Zhao B, Li L, Lu Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011;25:51-63
18. Chan SW, Lim CJ, Chong YF, et al. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011;286:7018-26
19. Paramasivam M, Sarkeshik A, Yates JR III, et al. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol Biol Cell 2011;22:3725-33
20. Oka T, Remue E, Meerschaert K, et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J 2010; 432:461-72
21. Oka T, Schmitt AP, Sudol M. Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene 2012;31:128-34
22. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun 2010;394:623-7
23. Kowalik MA, Saliba C, Pibiri M, et al. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology 2011;53:2086-96